Efficacy and Safety of Biphasic Insulin Aspart 30 in Combination With Metformin in Type 2 Diabetes (EUROMIX)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Type 2 diabetes for at least 6 months
Insulin naive. Short term insulin treatment (7 days or less within the last 6 months) is allowed
Previous treatment with oral antidiabetic drugs for at least 4 months
Judged by the investigator to be eligible for an insulin analogue plus oral antidiabetic drug treatment regimen
BMI below 40 kg/m2
HbA1c between 7-12%
Able and willing to perform self-plasma glucose monitoring
The receipt of any other investigational drug within 4 weeks before screening
A history of drug or alcohol abuse within the last 12 months
Severe, uncontrolled hypertension
Known or suspected allergy to trial products or related products